Crescent Biopharma Announces Grants of Inducement Awards

Each employee must remain in service through the applicable vesting dates for the corresponding options to become exercisable.

Rhea-AI Summary

Crescent Biopharma (CBIO) approved inducement options covering 31,200 ordinary shares for two non-executive employees on September 24, 2026.

The options have a 10-year term and a $14.24 exercise price, equal to the closing price of Crescent’s ordinary shares on Nasdaq on September 24. One-fourth of each employee’s options vest on the first anniversary of their start date, followed by one-forty-eighth monthly, subject to continued service through each vesting date. The awards were material to the employees’ acceptance of employment and are governed by Crescent’s amended 2025 Employment Inducement Incentive Award Plan.

News Explained

The 31,200 options are rights to buy shares, not shares issued now; if exercised, they could increase the share count and dilute existing holders.

Market Context

On Sep 9, Crescent disclosed an inducement grant covering 58,650 shares under the amended 2025 plan,...

Analysis

On Sep 9, Crescent disclosed an inducement grant covering 58,650 shares under the amended 2025 plan, providing a prior scale reference for this recurring award program; that record does not establish a market response to this notice.

Key Figures

Options granted: 31,200 shares Recipients: 2 employees Option term: 10 years +3 more

Options granted

31,200 shares

Aggregate grant to two non-executive employees

Recipients

2 employees

Non-executive employees

Option term

10 years

Granted options

Exercise price

$14.24 per share

Equal to the September 24, 2026 closing price

Initial vesting

One-fourth (1/4th)

Vests on the first anniversary of each employee's start date, subject to continuous service

Subsequent vesting

One-forty-eighth (1/48th) monthly

After initial vesting, subject to continuous service

Historical Context

3 past events · Latest: Sep 09

3 events

1. Sep 09

   Inducement awards

   24h Move

   -2.6%

   Prior grant covered 58,650 shares under the amended 2025 plan, with a 10-year option term.

2. Aug 03

   Inducement awards

   24h Move

   +2.8%

   Prior grant covered 19,425 shares under the 2025 plan, with a 10-year option term.

3. Jul 23

   Inducement awards

   24h Move

   -4.3%

   Prior grant covered 52,500 shares under the 2025 plan, with a 10-year option term.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

nasdaq listing rule 5635(c)(4)

1 terms

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., Sept. 25, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 31,200 shares of the Company’s ordinary shares to two non-executive employees as equity inducement awards under the Crescent Biopharma, Inc. 2025 Employment Inducement Incentive Award Plan, as amended (the “Inducement Plan”). The options were approved on September 24, 2026 and were material to each employee's acceptance of employment with Crescent, in accordance with Nasdaq Listing Rule 5635(c)(4).

The options were granted with a 10-year term and an exercise price equal to $14.24, the closing price per share of Crescent’s ordinary shares as reported by Nasdaq on September 24, 2026. The options granted to each employee shall vest and become exercisable as to one-fourth (1/4th) of the shares subject to the respective options on the first anniversary of the employee’s start date, and one-forty-eighth (1/48th) of the shares subject to the respective options shall vest and become exercisable monthly thereafter, in each case, subject to continuous service with Crescent through the applicable vesting dates. The options are subject to the terms of the Inducement Plan and the terms and conditions of an option agreement covering the applicable grant.

About Crescent Biopharma 

Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates (ADCs). By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies as single agents and as part of combination regimens to treat a range of solid tumors. For more information, visit www.crescentbiopharma.com and follow the Company on LinkedIn and X. 

Contacts

Investors

Amy Reilly
Chief Communications Officer
amy.reilly@crescentbiopharma.com
617-465-0586

Media

Jenna Poist
Director, Corporate Communications
jenna.poist@crescentbiopharma.com
781-671-5019

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What are the terms of Crescent Biopharma’s employee inducement options?

The options cover an aggregate of 31,200 ordinary shares for two non-executive employees, with a $14.24 exercise price and a 10-year term. One-fourth of each employee’s options vest on the first anniversary of their start date, followed by one-forty-eighth monthly, subject to continued service.